LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma
© 2020. The Author(s), under exclusive licence to Springer Nature America, Inc..
LINC01857 has been proven to be involved in glioma and breast cancer. However, the biological function of LINC01857 in diffuse large B-cell lymphoma (DLBCL) is poorly investigated. By accessing to the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEX), LINC01857 expression was found upregulated in both DLBCL tissues and cells. Cell proliferation and flow cytometry assays showed that LINC01857 promoted proliferation and cell cycle, but suppressed apoptosis in DLBCL cells. Bioinformatics analysis and luciferase reporter assay confirmed that LINC01857 may serve as a sponge for miR-141-3p and miR-141-3p may target MAP4K4. Mechanically, the regulatory action of miR-141-3p/MAP4K4 on DLBCL cellular behaviors was regulated by LINC01857. In addition, LINC01857 could increase the activity of PI3K/mTOR pathway and facilitate the EMT process in a miR-141-3p-mediated manner in DLBCL. Our data illustrated that the LINC01857/miR-141-3p/MAP4K4 might function as a promising therapeutic avenue for DLBCL treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Cancer gene therapy - 28(2021), 9 vom: 11. Sept., Seite 1046-1057 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Qian [VerfasserIn] |
---|
Links: |
---|
Themen: |
EC 2.7.1.1 |
---|
Anmerkungen: |
Date Completed 25.02.2022 Date Revised 28.01.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41417-020-00267-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM318768518 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM318768518 | ||
003 | DE-627 | ||
005 | 20231225170040.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41417-020-00267-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1062.xml |
035 | |a (DE-627)NLM318768518 | ||
035 | |a (NLM)33311569 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Qian |e verfasserin |4 aut | |
245 | 1 | 0 | |a LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.02.2022 | ||
500 | |a Date Revised 28.01.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
520 | |a LINC01857 has been proven to be involved in glioma and breast cancer. However, the biological function of LINC01857 in diffuse large B-cell lymphoma (DLBCL) is poorly investigated. By accessing to the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEX), LINC01857 expression was found upregulated in both DLBCL tissues and cells. Cell proliferation and flow cytometry assays showed that LINC01857 promoted proliferation and cell cycle, but suppressed apoptosis in DLBCL cells. Bioinformatics analysis and luciferase reporter assay confirmed that LINC01857 may serve as a sponge for miR-141-3p and miR-141-3p may target MAP4K4. Mechanically, the regulatory action of miR-141-3p/MAP4K4 on DLBCL cellular behaviors was regulated by LINC01857. In addition, LINC01857 could increase the activity of PI3K/mTOR pathway and facilitate the EMT process in a miR-141-3p-mediated manner in DLBCL. Our data illustrated that the LINC01857/miR-141-3p/MAP4K4 might function as a promising therapeutic avenue for DLBCL treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a MIRN141 microRNA, human |2 NLM | |
650 | 7 | |a MicroRNAs |2 NLM | |
650 | 7 | |a RNA, Long Noncoding |2 NLM | |
650 | 7 | |a MTOR protein, human |2 NLM | |
650 | 7 | |a EC 2.7.1.1 |2 NLM | |
650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
700 | 1 | |a Li, Bao |e verfasserin |4 aut | |
700 | 1 | |a Lu, Chang-Liang |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jing-Ye |e verfasserin |4 aut | |
700 | 1 | |a Gao, Min |e verfasserin |4 aut | |
700 | 1 | |a Gao, Wei |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer gene therapy |d 1997 |g 28(2021), 9 vom: 11. Sept., Seite 1046-1057 |w (DE-627)NLM075187256 |x 1476-5500 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2021 |g number:9 |g day:11 |g month:09 |g pages:1046-1057 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41417-020-00267-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 28 |j 2021 |e 9 |b 11 |c 09 |h 1046-1057 |